Skip to main content
49°
Rain
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
League of Women Voters SRI
League of Women Voters WS
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Aquestive Therapeutics, Inc.
< Previous
1
2
Next >
Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences
November 12, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AQST
Aquestive Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
November 04, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AQST
Aquestive Therapeutics to Present Subsequent Analysis of Pivotal Study for Anaphylm™ (epinephrine) Sublingual Film Demonstrating Comparable PK and PD Data to Epinephrine Injection Regardless of Variable Placement or Intraoral Movement at American College
October 25, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AQST
Aquestive Therapeutics Announces Positive Topline Results from Oral Allergy Syndrome (OAS) Challenge Study for Anaphylm™ (epinephrine) Sublingual Film
October 24, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AQST
Aquestive Therapeutics to Report Third Quarter 2024 Financial Results and Recent Business Highlights on November 4 and Host Conference Call on November 5 at 8:00 a.m. ET
October 21, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AQST
Aquestive Therapeutics Spotlights its Innovative Epinephrine Delivery Pipeline at Virtual Investor Day
September 27, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AQST
Aquestive Therapeutics to Hold Virtual Investor Day to Provide Pipeline Updates on September 27th
September 09, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AQST
Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences
August 22, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AQST
Aquestive Therapeutics Comments on Recent FDA Approval of Non-Injection-Based Epinephrine Product for the Treatment of Anaphylaxis and Reiterates Expected Timing for NDA Filing of Anaphylm™
August 14, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AQST
Aquestive Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
August 06, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AQST
Aquestive Therapeutics Reports Positive Topline Data for Anaphylm™ (epinephrine) Sublingual Film from Self-Administration Study
July 25, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AQST
Aquestive Therapeutics to Report Second Quarter 2024 Financial Results and Recent Business Highlights on August 6 and Host Conference Call on August 7 at 8:00 a.m. ET
July 23, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AQST
Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism
June 27, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AQST
Aquestive Therapeutics Reports Positive Topline Data from Temperature / pH Study of Anaphylm™ (epinephrine) Sublingual Film
June 25, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AQST
Aquestive Therapeutics to Join the Russell 3000® and Russell 2000® Indexes Effective June 28, 2024
June 18, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AQST
Aquestive Therapeutics Announces Executive Appointments and Builds Commercial Capabilities
June 03, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AQST
Aquestive Therapeutics to Present Anaphylm™ (epinephrine) Sublingual Film Pharmacokinetic and Pharmacodynamic Data At 2024 Eastern Allergy Conference
May 28, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AQST
Aquestive Therapeutics to Participate in The Citizens JMP Life Sciences Conference
May 09, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AQST
Aquestive Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
May 07, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AQST
Aquestive Therapeutics Receives U.S. FDA Approval and Market Access for Libervant™ (diazepam) Buccal Film in Pediatric Patients Ages 2 to 5 and Provides Update on Anaphylm™ (epinephrine) Sublingual Film
April 29, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AQST
Aquestive Therapeutics to Report First Quarter 2024 Financial Results and Recent Business Highlights on May 7 and Host Conference Call on May 8 at 8:00 a.m. ET
April 25, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AQST
Aquestive Therapeutics to Present Crossover Study Data for Libervant™ (diazepam) Buccal Film at 76th Annual Meeting of the American Academy of Neurology
April 12, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AQST
Aquestive Therapeutics Strengthens Board of Directors with Experienced Biotech Executive
April 01, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AQST
EBS
GMDA
Aquestive Therapeutics Announces Closing of Underwritten Public Offering of Common Stock
March 25, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AQST
Aquestive Therapeutics Announces Pricing of $75 Million Underwritten Public Offering of Common Stock
March 19, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AQST
Aquestive Therapeutics Announces Proposed Public Offering of Common Stock
March 19, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AQST
Aquestive Therapeutics Announces Pivotal Study for Anaphylm™ (epinephrine) Sublingual Film Successfully Meets Primary and Secondary Endpoints and Provides Clinical Development Update Following FDA Meeting
March 14, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AQST
Aquestive Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
March 05, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AQST
Aquestive Therapeutics to Report Fourth Quarter 2023 Financial Results and Recent Business Highlights on March 5 and Host Conference Call on March 6 at 8:00 a.m. ET
February 21, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AQST
Aquestive Therapeutics to Present Anaphylm™ (epinephrine) Sublingual Film Pharmacokinetic and Pharmacodynamic Data at the 2024 AAAAI Annual Meeting
February 15, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AQST
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.